Skip to main content

Advertisement

Table 1 PIK3CA mutational status and clinical features in gastric cancers

From: Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review

Features Total PIK3CA mutation p value
Mutant Wild-Type
n = 208 n = 25 (12 %) n = 183 (88 %)
Age (year)     0.30
 Mean ± SE 208 67.4 ± 2.1 69.8 ± 0.8  
Sex     0.41
 Male 148 16 (11) 132 (89)  
 Female 60 9 (15) 51 (85)  
Location     0.22
 Upper 75 13 (17) 62 (83)  
 Middle 65 6 (9) 59 (91)  
 Lower 68 6 (9) 62 (91)  
Tumor depth     0.09
 T1 105 18 (17) 87 (83)  
 T2 29 2 (6) 29 (94)  
 T3 42 2 (5) 42 (95)  
 T4 25 3 (11) 25 (89)  
Lymph node involvement     0.73
 Absent 135 17 (13) 118 (87)  
 Present 73 8 (11) 65 (83)  
Stage     0.78
 I 123 17 (14) 106 (86)  
 II 40 4 (10) 36 (90)  
 III 26 2 (8) 24 (92)  
 IV 19 2 (11) 17 (89)  
Lauren classification     0.79
 Intestinal 138 16 (12) 122 (88)  
 Diffuse 70 9 (13) 61 (87)  
Venous invasion     0.05
 Absent 111 18 (16) 93 (84)  
 Present 95 7 (7) 88 (93)  
Lymphatic invasion     0.40
 Absent 117 16 (14) 101 (86)  
 Present 91 9 (10) 82 (90)  
LINE-1 methylation level (%)     0.19
 Mean ± SE 208 74.9 ± 2.6 71.2 ± 1.0  
  1. PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, LINE-1 long interspersed nucleotide element-1, SE standard error